204 related articles for article (PubMed ID: 9437500)
1. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
[TBL] [Abstract][Full Text] [Related]
2. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
4. Impaired CD25 expression and soluble CD25-IL-2R alpha receptor release by anti-CD3 stimulated peripheral blood mononuclear cells in Hodgkin's disease patients.
Frydecka I; Mazur G
Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):127-30. PubMed ID: 8915517
[TBL] [Abstract][Full Text] [Related]
5. [The serum levels of soluble interleukin-2 receptor in patients with malignant lymphocytic proliferative disorders].
Xu J; Wang B
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):82-4. PubMed ID: 10921108
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
Remberger M; Ringdén O
Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
[TBL] [Abstract][Full Text] [Related]
9. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
[TBL] [Abstract][Full Text] [Related]
10. [Measurement of five cytokines in the serum of malignant lymphoma patients].
Zhu H; Wang Y; Han X
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):85-8. PubMed ID: 10921109
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies.
Nakase K; Tsuji K; Tamaki S; Tanigawa M; Ikeda T; Miyanishi E; Shiku H
Cancer Detect Prev; 2005; 29(3):256-9. PubMed ID: 15899555
[TBL] [Abstract][Full Text] [Related]
12. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
13. A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma.
Vacca A; Di Stefano R; Frassanito A; Iodice G; Dammacco F
Clin Exp Immunol; 1991 Jun; 84(3):429-34. PubMed ID: 2044221
[TBL] [Abstract][Full Text] [Related]
14. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
Kuku I; Bayraktar MR; Kaya E; Erkurt MA; Bayraktar N; Cikim K; Aydogdu I
Mediators Inflamm; 2005 Aug; 2005(3):171-4. PubMed ID: 16106104
[TBL] [Abstract][Full Text] [Related]
15. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
[TBL] [Abstract][Full Text] [Related]
16. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma.
Stasi R; Stipa E; Masi M; Oliva F; Sciarra A; Perrotti A; Zaccari G; Papa G
Thromb Haemost; 1993 Oct; 70(4):568-72. PubMed ID: 8115979
[TBL] [Abstract][Full Text] [Related]
17. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
[TBL] [Abstract][Full Text] [Related]
18. [Changes of serum interleukin 2 and soluble interleukin 2 receptor and their clinical significance in multiple myeloma].
Wang Z; Li D; Yang J
Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):439-41. PubMed ID: 9387297
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
Kitaoka S; Shiota G; Kawasaki H
Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
[TBL] [Abstract][Full Text] [Related]
20. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation.
Foley R; Couban S; Walker I; Greene K; Chen CS; Messner H; Gauldie J
Bone Marrow Transplant; 1998 Apr; 21(8):769-73. PubMed ID: 9603399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
